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CObjectives: To assess the cost-effectiveness of oral capecitabine com-
paredwith intravenous bolus 5-fluorouracil/leucovorin (5-FU/LV) in the
adjuvant treatment of stage III colon cancer in Taiwan from payer (Bu-
reau of National Health Insurance [BNHI]) perspectives. Methods: A
health state-transition model was developed to estimate the incre-
mental costs and effectiveness of capecitabine versus 5-FU/LV. The
time horizons studied were: treatment duration (24 weeks) plus 36
months, 48 months, 60 months, 120 months, and lifetime. Costs were
expressed in Taiwanese new dollars (NT$). Clinical outcomes, medical
resource use, and utilities were extracted from published sources. Unit
costs were estimated from BNHI fee schedules, published sources, and
local expert opinion. Outcomes and future costswere discounted at 3%.
Cost-effectiveness was expressed as cost per quality-adjusted life-
month (QALM). The effects of uncertainty were explored through a
one-way sensitivity analysis. Results: For the 24-week time period, O
r
i
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al So
oi:10.1016/j.jval.2011.01.010rug acquisition costs were higher for capecitabine than 5-FU/LV
NT$114,405 vs. NT$4,904 per patient); however, these were offset by
he higher administration costs of 5-FU/LV (NT$2,573 vs. NT$204,201
er patient). Overall direct costs for the 24-week treatment periodwere
ess with capecitabine than 5-FU/LV (NT$129,327 vs. NT$233,873 per
atient). Cost savings with capecitabine were also evident when longer
ime horizons were considered. Over a lifetime, the projected survival
enefit for capecitabinewas 7 QALMs. Conclusions: From the perspec-
ives of the BNHI and society in Taiwan, capecitabine not only saves
osts but also improves health outcomes comparedwith 5-FU/LV in the
djuvant treatment of stage III colon cancer.
eywords: 5-fluorouracil/leucovorin, adjuvant therapy, capecitabine,
olon cancer, pharmacoeconomics.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Colorectal cancer is on a rapidly rising trend in Asia [1]. In Taiwan,
colorectal cancer is the second most commonly diagnosed cancer
and the third leading cause of death after lung cancer and liver
cancer. According to a statistics report from the Taiwanese De-
partment of Health, there were approximately 62,400 patients
with colorectal cancer in 2006, and almost 4,300 patients died from
this disease giving an unadjustedmortality rate of 18.7 per 100,000
population [2]. In addition, the relatedmedical expenditurewas an
estimated Taiwanese new dollar (NT) $3.7 billion in 2006 [3].
Treatment for colon cancer depends on both the disease stage
and the health status of the patient. Current treatment guidelines
recommend surgical resection followed by adjuvant chemother-
apy [4,5] to prevent disease recurrence and prolong survival time
[6]. Until recently, the standard adjuvant treatment for stage III
colon cancer was intravenous bolus 5-fluorouracil (5-FU) and leu-
covorin (LV), either weekly or monthly, over a period of 6 to 8
* Address correspondence to: Li-Tzong Chen, MD, PhD, No. 367, Sh
E-mail: leochen@nhri.org.tw.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.months. Although the efficacy of adjuvant 5-FU/LV is well estab-
lished, the intravenous (i.v.) administration schedules are incon-
venient and require repeated visits to the clinic.
Capecitabine (Xeloda, F. Hoffmann-La Roche, Basel, Switzer-
land) is an oral fluoropyrimidine that generates 5-FUpreferentially
in tumor tissue through a three-step enzymatic cascade [7]. The
efficacy of capecitabine as first-line treatment for metastatic colo-
rectal cancer compared with monthly bolus i.v. 5-FU/LV (Mayo
Clinic regimen) has been demonstrated in terms of improved re-
sponse rates (26% vs. 17%), and at least equivalent progression-
free and overall survival [8].
More recently, the study of Xeloda in adjuvant colon cancer
therapy (X-ACT) has been conducted to investigate the use of
capecitabine as adjuvant therapy for stage III colon cancer [9]. The
esults demonstrated that capecitabine was significantly superior
n terms of relapse-free survival (hazard ratio [HR], 0.86; 95% CI,
.74–0.99; P  0.04). In addition, an improved safety profile was
oted in favor of capecitabine [10]. On the basis of these findings,
Li Road, Tainan, 70465, Taiwan.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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648 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 4 7 – 6 5 1capecitabine is now a recognized option for the adjuvant treat-
ment of patients with stage III colon cancer [4,5].
Because of the increasing costs of health care, the decision to
eimburse a new treatment is not necessarily based on efficacy
lone. Economic evaluation is nowan important component of the
egulatory decision-making process, and helps with the allocation
f limited resources. To date, few pharmacoeconomic studies
ave been conducted to compare the capecitabine versus 5-FU/LV
n adjuvant treatment. In the study by Cassidy et al. [11], capecit-
bine was projected to be cost saving by an average amount of
pproximately £3653 (pound sterling) per patient from UK Na-
ional Health Service perspective. The result of cost-saving was
lso demonstrated in the Netherlands (Jansman [12]) and Japan
Shiroiwa [13]). Considering the difference in clinical practice and
ealth care cost among countries, we are interested in under-
tanding the Taiwanese local setting. TheMayo regimen, reported
n Cassidy et al. [11], is not the common use for Taiwan clinical
ractice. The objective of this pharmacoeconomic study was to
ssess the cost-effectiveness of capecitabine versus 5-FU/LV as
djuvant therapy in stage III colon cancer in Taiwan from the
ayer (the Bureau of National Health Insurance [BNHI]) perspec-
ive.
Methods
Study design
The cost-effectiveness analysis used was based on a health state-
transition model that was designed to evaluate the cost-effective-
ness of adjuvant therapy with capecitabine versus 5-FU/LV in pa-
tients with resected stage III colon cancer. An overview of the
study design was shown in Figure 1. The time horizons studied
were: treatment duration (24 weeks) plus 36 months, 48 months,
60 months, 120 months, and lifetime.
Three discrete disease states were used (stable disease, pro-
gressive disease, and death) and each disease state was assigned a
utility value (a number reflecting the quality of life in that disease
state, the number being 0 for death). A model was then created in
which 100 patients with confirmed stage III colon carcinoma were
given capecitabine and 100 were given 5-FU/LV. Progression from
one disease state to the next was simulated using clinical data
from the 2005 X-ACT study [9] comparing capecitabine and
5-FU/LV treatment. The time spent in each disease state for each
time period for each treatment was calculated as life-months, and
these were multiplied by the utility value for the disease state to
obtain quality-adjusted life-months (QALMS). Direct costs were
then calculated for each time period and compared directly be-
tween capecitabine and 5-FU/LV for the 24-week treatment period
and in terms of cost savings per patient per QALM gained by using
capecitabine instead of 5-FU/LV for the other time periods. Amore
detailed explanation of the protocol is found below.
Survival analysis
The model consisted of three discrete states: stable disease (pre-
relapse, disease-free, and relapse-free); post-relapse; and death. A
relapse event was defined as an instance of relapse, new colon
cancer, or death due to colon cancer or cancer treatment. Using
this definition, it was possible to divide overall survival into pre-
and post-relapse periods using the relapse-free and overall sur-
vival data from the X-ACT trial [9]. Relapse and death were han-
dled as one-time deviations from the two time periods.
It was assumed that 100 patients with confirmed stage III colon
carcinoma were assigned to capecitabine treatment and that 100
similar patients were assigned to 5-FU/LV treatment. Time spent
in each health state was estimated using partitioned survival of
the clinical trial data (intent-to-treat [ITT] population). The clinicaltrial data on time-to-relapse and overall survival were described
using non-parametric Kaplan-Meier estimates. Log-normal distri-
bution was used to extrapolate the lifetime survival beyond the
trial period described in the X-ACT study (themedian follow-up in
the X-ACT study was 3.8 years).
The outcomes of each state were measured as life-months
gained and quality-adjusted life months (QALMs) gained, where
QALMs are the time spent in each health state weighted by the
quality of life or utility of that health state. Lifetime QALMs were
the sum of the QALMs from each state.
Utility estimation
The utility values used to calculate QALMs were taken from the
published literature [14]. It was assumed that there was no differ-
ence in utility value during the 24-week chemotherapy period be-
tween capecitabine and 5-FU/LV (utility  0.8). In addition, we
divided the period of post-treatment into two time periods (pre-
relapse and post-relapse) to reflect the utility difference in post-
treatment; and a utility of 0 was assumed in death. We used the
data from the survival analysis for the 5-FU/LV control arm to
determine what percent of patients would have been in the pre-
relapse and post-relapse health states at 13 to 25months and 37 to
60 months of follow-up and linked this number to the relative
utility values derived from Ramsey et al. [14] (0.82 for 13–24
months and 0.79 for 37–60 months). Thus, the implied utility val-
ues for the pre-relapse and post-relapse periodswere estimated to
be 0.86 and 0.59.
Medical resource utilization
The components of medical resource utilization considered
were determined by referring to the UK pharmacoeconomic
analysis of the X-ACT study [11], the European Society for Med-
ical Oncology (ESMO) minimum clinical recommendations for
diagnosis, adjuvant treatment, and follow-up of colon cancer
[15], the National Comprehensive Cancer Network (NCCN) Clin-
ical Practice Guidelines in Oncology [16], and the Taiwan local
treatment guideline [17].
Medical resource utilization was divided into two periods –
treatment and post-treatment. To determine how these resources
are allocated and used in Taiwan, a panel of 12 Taiwanese colo-
rectal surgeons and medical oncologists was assembled, and a
survey conducted among them (the “expert panel survey”) in order
to determine local treatment regimens, drug administration pat-
Fig. 1 – Overview of study design. 5-FU/LV, 5-fluorouracil/
leucovorin; BNHI, Bureau of National Health Insurance; PE,
pharmacoeconomic.terns, and adverse effects (AEs)management during the treatment
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649V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 4 7 – 6 5 1and post-treatment periods. In the Taiwan local expert panel sur-
vey results, 69.6% patients in Taiwan received outpatient depart-
ment bolus 5-FU regimens (Roswell Park vs. Mayo Clinic was 74%
vs. 26%) and 30.4% patients received an inpatient department in-
fusion of 5-FU regimen (high-dose AIO vs. de Gramont was 57% vs.
43%). This information was then also used for cost assessment.
The major components of the cost assessment were the phy-
sician consultation, chemotherapy regimen, drug dosing, drug ad-
ministration, administration frequency, treatment duration, and
hospitalizations. Resource use associated with managing treat-
ment-related AEs was also considered, i.e. medications required
for treatment-related AEs, associated hospital admissions, gen-
eral practitioner or specialist consultations, and accident and
emergency visits. Relevant data were derived from the UK X-ACT
cost-effectiveness study [11]. The expert panel survey also in-
cluded themedical resource utilization for the post-treatment pe-
riod, and was sub-classified into three states (pre-relapse, relapse
event, and post-relapse). In the pre-relapse and post-relapse
states, maintenance (regular monitoring) was the major medical
intervention. Once relapse occurred, it was assumed that patients
underwent surgery or received chemotherapy if diagnosed with
metastases.
Costs
Chemotherapy drug costs were based on the 2006 BNHI refer-
ence list for drugs [3], and the costs of consultations, drug infu-
sion, hospital stay, accident and emergency visits were based
on the 2006 BNHI fee schedule for medical services [18]. The
osts of terminal care were extracted from the study by Lo [19].
summary of unit costs used in the model is presented in
able 1.
The total direct cost of each treatment was calculated by mul-
Table 1 – Unit cost estimates.
Cost category Unit cost
(NT$)
Source
Chemotherapy drug costs
(per mg)
Capecitabine $0.27 BNHI RLD 2006
5-Fluorouracil $0.11 BNHI RLD 2006
Leucovorin $2.95 BNHI RLD 2006
Drug administration
Physician consultation $350 BNHI FSMS 2006
Chemotherapy treatment
consultation
$2,000 BNHI FSMS 2006
Intravenous chemotherapy
administration
$7,201 Expert panel survey
Adverse event management
Cost per hospital day $1,852 BNHI FSMS 2006
GP/specialist office
consultation
$320 BNHI FSMS 2006
GP/specialist home visit $600 BNHI FSMS 2006
Accident and emergency visit $758 BNHI FSMS 2006
Post-treatment
Pre-relapse maintenance
(per month)
$2,283 Expert panel survey
Relapse event $245,106 Expert panel survey
Post-relapse maintenance
(per month)
$3,948 Expert panel survey
Costs related to death $403,539 Lo 2002 [19]
Costs are expressed in Taiwanese new dollar (NT$).
BNHI, Bureau of National Health Insurance of Taiwan; FSMS, fee
schedule for medical services; GP, general practitioner; RLD, refer-
ence list for drugs.iplying the unit cost by medical resource utilization during eacheriod. An incremental cost-effectiveness ratio, defined as the ad-
itional cost per QALM gained, was calculated by dividing the dif-
erence in total costs of the two interventions by the increase in
ALM. Costs were expressed in New Taiwanese Dollars (NT$) at
007 values.
Discounting
In order to estimate the present value of future costs and benefits,
an annual discount rate of 3%was used to discount benefits and all
future costs. The discount rate was based on the “Guidelines of
Methodological Standards for Pharmacoeconomic Evaluation” of
Taiwan (version 1.0) [20].
Sensitivity analyses
One-way sensitivity analyses were performed to test the robust-
ness of the model. The sensitivity analyses varied key assump-
tions in the model, including the acquisition costs of chemother-
apy drugs and medications for AEs, drug administration costs,
utilities, and discount rates.
Results
Clinical effectiveness
According to the Kaplan–Meier projection, patients who received
capecitabine had a better rate of overall survival than those who
received i.v. 5-FU/LV. At 36 months, the rate of overall survival in
patients who were treated with capecitabine was 81.3% compared
with 77.6% of patients who received i.v. 5-FU/LV (an absolute dif-
ference of 3.7%). In the model, the projected survival gains with
capecitabine treatment at 36 and 48months were 0.48 QALMs and
0.75 QALMs, respectively. When the model was used to extrapo-
late to longer horizons — 5 years, 10 years, or a lifetime — the
projected gain in QALMs continued to increase with capecitabine
treatment, even after taking into account adjustments for quality
of life and discounting. Over a lifetime, for example, the QALM
advantage for capecitabine treatment versus 5-FU/LVwidened to 7
months.
Table 2 – Estimated per patient costs of capecitabine
and 5-FU/LV during the 24-week treatment period.
Cost type Mean cost per patient (NT$)
Capecitabine 5-FU/LV Net
savings
Direct medical costs
Chemotherapy drugs 114,405 4,904 109,501
Visits for drug
administration
2,573 204,201 201,628
Hospital use for AEs 2,087 2,404 317
Physician consultations
for AEs
460 461 1
Medications for treating
AEs
7,803 19,904 12,101
Chemotherapy
treatment
consultation
2,000 2,000 0
Total 129,327 233,873 104,546
Costs are expressed in Taiwanese new dollar (NT$).
5-FU/LV, 5-fluorouracil/leucovorin; AEs, adverse events.
650 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 4 7 – 6 5 1Chemotherapy costs
Chemotherapy costs included chemotherapy drug acquisition and
drug administration costs. The estimated mean acquisition costs
of capecitabine were higher than those of 5-FU/LV (NT$114,405 vs.
NT$4,904 per patient), but the estimated drug administration costs
of 5-FU/LV were considerably higher than those of capecitabine,
which was mainly accounted for by the repeated visits for i.v.
administration (NT$204,201 vs. NT$2573 per patient).
AE management costs
The improved safety profile of capecitabine compared with i.v.
bolus 5-FU/LV was reflected in lower AE management costs, espe-
cially in the cost of medications required for treating AEs. In this
study, capecitabine significantly reduced the need for more ex-
pensive drugs, such as granulocyte-colony stimulating factor for
neutropenia and amphotericin B for stomatitis events. The esti-
mated mean cost of medications for the management of AEs with
capecitabine treatment was NT$7,803 per patient compared with
NT$19,904 per patient with 5-FU/LV treatment (Table 2). A similar
trend was observed in the cost of hospitalization for AEs.
Total costs
Table 3 shows the estimated incremental cost savings according
to the model for capecitabine versus 5-FU/LV over the time hori-
zon studied. Although themean acquisition cost of chemotherapy
for capecitabinewas higher than for 5-FU/LV, the total directmed-
ical costs, after taking drug administration and AE management
costs into consideration, were lower with capecitabine. The esti-
mated total direct costs for 5-FU/LV treatment were NT$233,873
per patient, almost twice that of capecitabine treatment
(NT$129,327 per patient).
Table 3 – Projected gains in QALMs and incremental
cost savings for capecitabine versus 5-FU/LV by time
horizon.
Time horizon
(months)
Gain in
QALMs
Incremental cost savings
(NT$ per patient)
36 0.48 125,934
48 0.75 126,097
60 1.04 125,686
120 2.51 121,001
Lifetime 7.03 103,940
Costs are expressed in Taiwanese new dollar (NT$).
5-FU/LV, 5-fluorouracil/leucovorin; QALMs, quality-adjusted life
months.
Table 4 – One-way sensitivity analysis.
Parameter Range
Mean milligram of capecitabine use 430137–414180
Mean milligram of 5-FU use 19820–19147
Mean milligram of LV use 973–937
Health state utilities 20%
Cost per drug administration visit 20%
Total AE medication costs 20%
Post-treatment costs 20%
Discount rate for costs and benefits 0.05
Costs are expressed in Taiwanese new dollar (NT$).
5-FU, 5-fluorouracil; AE, adverse event; LV, leucovorin; QALM, quality
* Treatment period.
† Lifetime estimate.Cost-effectiveness analysis
Capecitabine was at least as effective as 5-FU/LV treatment in
terms of QALMs, and the total estimated costs associated with
capecitabine therapy were also lower than with 5-FU/LV treat-
ment from the perspectives of BNHI (Tables 2 and 3).
Considering post-treatment costs as well as costs accrued dur-
ing treatment, the projected net cost savings were still positive
over the time horizon. There were cost savings of NT$125,934 and
NT$103,940 in the 36 month and in the lifetime from the BNHI
perspective. The saving decrease is attributed to the longer recur-
rence-free survival and overall survival induced by capecitabine.
Sensitivity analysis
A one-way sensitivity analysis was performed on key parameters
by varying the values of model inputs by 20% (Table 4). Varying
the chemotherapy drug doses and the costs of medications re-
quired for AEs had only a small effect on cost savings. A 20% vari-
ation in the cost of each drug administration visit, however, lead to
a 2.25-fold variation in cost savings (NT$144,872 to NT$64,221).
The sensitivity analysis confirmed the cost savings for capecit-
abine versus 5-FU/LV. The QALM benefits of capecitabine versus
5-FU/LVwere alsomaintained after adjusting the base-case values
of utilities and discount rate.
Discussion
The X-ACT trial demonstrated that oral capecitabine was at least
as effective as bolus 5-FU/LV in terms of disease-free survival and
overall survival, and significantly improved relapse-free survival
when given as a 24-week course of adjuvant therapy in patients
with resected stage III colon cancer [9]. In the present cost-effec-
tiveness analysis, we used a health-state transition model to ex-
trapolate the X-ACT efficacy data to longer time horizons. We also
applied cost estimates from Taiwanese published sources and ex-
pert opinion to the medical resource utilization data from the X-
ACT study. Our analysis indicates that capecitabine prolongs qual-
ity-adjusted survival when compared with 5-FU/LV and saves
costs from the perspectives of BNHI over a range of time horizons.
Therefore, capecitabine can be viewed as a “dominant” adjuvant
treatment strategy for patients with colon cancer in Taiwan.
From the BNHI payer’s perspective, although the acquisition cost
of capecitabine was higher than that of 5-FU/LV, this cost was more
than offset by the administration costs required for i.v. 5-FU/LV. The
need for fewer anti-emetics, triazoles, and cytokines for themanage-
ment of AEs and associated hospital visits with capecitabine versus
5-FU/LV also resulted in cost savings. Overall, the net cost savings in
direct costs during the treatment period with capecitabine versus
Cost savings (NT$) Lifetime QALMs
102,384–106,708* No change–no change
104,582–104,510* No change–no change
104,598–104,492* No change–no change
No change–no change† 8.6–5.3
144,872–64,221* No change–no change
106,966–102,126* No change–no change
106,494–103,819† No change–no change
104,546* 5.3
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651V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 4 7 – 6 5 15-FU/LV were NT$104,546 per patient. Savings in direct costs with
capecitabine were also observed over longer time horizons and
ranged from approximately NT$103,000 to NT$125,500.
The trends observed in the present analysis have been docu-
mented in other pharmacoeconomic studies comparing capecit-
abine with i.v. bolus 5-FU/LV in the adjuvant setting [11–13,21]. As
in the present study, the other analyses reported that the higher
acquisition cost of capecitabine was partially or completely offset
by the higher administration costs of i.v. 5-FU/LV. Indirect costs,
such as travel cost and productivity cost, have also been reported
to be lower with capecitabine [11,21].
Although we were able to estimate some resource utilization
componentsandunit costs fromlocal sourcesandexpertpanel opin-
ions, other inputs used in the current analysis were derived from
other countries and their relevance to the Taiwanese population is
unknown. TheX-ACT study, an international studywith someAsian
centers, didnot includeanyTaiwanese centers. In addition, there are
noTaiwan local health-related quality of life data or utility data from
patientswith colorectal cancer thatwecoulduse inour study.That is
why we further divided the utility of post-treatment into two time
periods (pre-relapse and post-relapse), which adjusted for utility dif-
ferences during post-treatment. Furthermore, the medical resource
utilization was calculated by the construction of a standard therapy
regime derived from a local expert panel survey and not from anal-
ysis of real data from actual patients.
However, the sensitivity analysis, which varied key model in-
puts, supported the findings of the case-based analysis and sug-
gests that the findings of the present analysis are robust.
Conclusions
TheX-ACTstudydemonstrated capecitabinewasat least as effective
as 5-FU/LV in adjuvant treatment for stage III colon cancer. The cur-
rent pharmacoeconomic analysis further found that capecitabine
not only saves costs, but also improves health outcomes compared
with 5-FU/LV from the perspective of the BNHI in Taiwan. Because of
the pressures of increasing health costs, the use of capecitabine is
likely to become an option that will effectively decrease some of the
budget pressure for health providers and the BNHI.
Source of financial support: Roche Products Ltd., Taipei, Taiwan.
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